Pacira BioSciences Toekomstige groei

Future criteriumcontroles 3/6

Pacira BioSciences zal naar verwachting groeien in winst en omzet met respectievelijk 27.3% en 3.1% per jaar. De winst per aandeel zal naar verwachting groeien met 31.1% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 6.4% zijn.

Belangrijke informatie

27.3%

Groei van de winst

31.1%

Groei van de winst per aandeel

Pharmaceuticals winstgroei	23.7%
Inkomstengroei	3.1%
Toekomstig rendement op eigen vermogen	6.4%
Dekking van analisten	Good
Laatst bijgewerkt	22 Oct 2024

Recente toekomstige groei-updates

Pacira BioSciences, Inc. Just Missed Earnings - But Analysts Have Updated Their Models

May 10

Recent updates

Pacira BioSciences, Inc. (NASDAQ:PCRX) Not Doing Enough For Some Investors As Its Shares Slump 34%

Sep 06

Little Excitement Around Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Revenues As Shares Take 29% Pounding

Jul 23

These 4 Measures Indicate That Pacira BioSciences (NASDAQ:PCRX) Is Using Debt Safely

Jun 07

Pacira BioSciences, Inc. Just Missed Earnings - But Analysts Have Updated Their Models

May 10

Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Intrinsic Value Is Potentially 26% Below Its Share Price

Jul 07

Is Pacira BioSciences (NASDAQ:PCRX) A Risky Investment?

Apr 18

We Think Pacira BioSciences (NASDAQ:PCRX) Can Stay On Top Of Its Debt

Dec 28

Assessing Pacira BioSciences' Growth Prospects

Oct 20

Pacira BioSciences guides Q3 revenue below consensus

Oct 13

Pacira, Sevāredent team up to expand access to pain drug Exparel for dental procedures

Sep 27

EMA panel backs expanding indication for Pacira's postsurgical pain treatment in kids

Sep 20

Pacira BioSciences records 17.7% sequential growth in August revenue

Sep 13

Pacira BioSciences provides update on July product sales

Aug 10

Pacira BioSciences Q2 2022 Earnings Preview

Aug 02

Pacira BioSciences sees Q2 revenue below consensus

Jul 14

Winst- en omzetgroeiprognoses

NasdaqGS:PCRX - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	699	73	161	164	7
12/31/2025	654	35	166	185	8
12/31/2024	692	72	155	195	8
6/30/2024	690	64	185	194	N/A
3/31/2024	682	70	173	185	N/A
12/31/2023	675	42	139	155	N/A
9/30/2023	666	7	130	149	N/A
6/30/2023	669	-5	127	147	N/A
3/31/2023	669	-10	105	134	N/A
12/31/2022	667	16	115	145	N/A
9/30/2022	654	21	93	126	N/A
6/30/2022	614	39	102	144	N/A
3/31/2022	580	38	104	144	N/A
12/31/2021	542	42	80	126	N/A
9/30/2021	513	62	98	149	N/A
6/30/2021	503	174	83	129	N/A
3/31/2021	443	148	39	83	N/A
12/31/2020	430	146	39	77	N/A
9/30/2020	421	126	28	56	N/A
6/30/2020	408	-10	13	35	N/A
3/31/2020	435	0	58	73	N/A
12/31/2019	421	-11	60	71	N/A
9/30/2019	394	2	58	66	N/A
6/30/2019	372	8	53	64	N/A
3/31/2019	354	7	44	55	N/A
12/31/2018	337	0	34	49	N/A
9/30/2018	321	-4	27	45	N/A
6/30/2018	305	-11	7	25	N/A
3/31/2018	292	-33	N/A	15	N/A
12/31/2017	287	-43	N/A	18	N/A
9/30/2017	280	-51	N/A	18	N/A
6/30/2017	281	-66	N/A	33	N/A
3/31/2017	280	-54	N/A	37	N/A
12/31/2016	276	-38	N/A	33	N/A
9/30/2016	273	-36	N/A	33	N/A
6/30/2016	267	-11	N/A	26	N/A
3/31/2016	256	-3	N/A	26	N/A
12/31/2015	249	2	N/A	28	N/A
9/30/2015	241	10	N/A	26	N/A
6/30/2015	231	4	N/A	29	N/A
3/31/2015	219	-1	N/A	30	N/A
12/31/2014	198	-14	N/A	27	N/A
9/30/2014	169	-31	N/A	6	N/A
6/30/2014	141	-43	N/A	-13	N/A
3/31/2014	111	-52	N/A	-34	N/A
12/31/2013	86	-64	N/A	-44	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachte winstgroei PCRX ( 27.3% per jaar) ligt boven de spaarquote ( 2.6% ).

Winst versus markt: De winst van PCRX ( 27.3% per jaar) zal naar verwachting sneller groeien dan de US markt ( 15.4% per jaar).

Hoge groeiwinsten: De winst van PCRX zal naar verwachting de komende 3 jaar aanzienlijk groeien.

Omzet versus markt: De omzet van PCRX ( 3.1% per jaar) zal naar verwachting langzamer groeien dan de markt US ( 8.8% per jaar).

Hoge groei-inkomsten: De omzet van PCRX ( 3.1% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Het rendement op eigen vermogen PCRX zal naar verwachting over 3 jaar laag zijn ( 6.4 %).

Pacira BioSciences Toekomstige groei

Future criteriumcontroles 3/6

Belangrijke informatie

Recente toekomstige groei-updates

Price target decreased by 46% to US$20.83

Pacira BioSciences, Inc. Just Missed Earnings - But Analysts Have Updated Their Models

Consensus EPS estimates fall by 21%

Pacira BioSciences, Inc. Updates Sales Guidance for the Full Year 2023

Price target decreased by 9.5% to US$55.89

Pacira BioSciences, Inc. Provides Earnings Guidance for the Full-Year 2023

Recent updates

Pacira BioSciences, Inc. to Report Q3, 2024 Results on Nov 06, 2024

Pacira BioSciences, Inc. Announces Chief Financial Officer Changes

Pacira BioSciences, Inc. Announces New Product-Specific J-Code for EXPAREL Effective January 1, 2025

DOMA Perpetual Capital Management Sends Letter to the Board of Directors of Pacira Biosciences

Investor sentiment improves as stock rises 15%

Pacira Biosciences, Inc. Announces Board Changes

Pacira BioSciences, Inc. (NASDAQ:PCRX) Not Doing Enough For Some Investors As Its Shares Slump 34%

Investor sentiment deteriorates as stock falls 44%

CEO & Director recently bought US$100k worth of stock

Price target decreased by 46% to US$20.83

New major risk - Share price stability

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Little Excitement Around Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Revenues As Shares Take 29% Pounding

Pacira BioSciences, Inc. to Report Q2, 2024 Results on Jul 30, 2024

Investor sentiment deteriorates as stock falls 20%

These 4 Measures Indicate That Pacira BioSciences (NASDAQ:PCRX) Is Using Debt Safely

Investor sentiment improves as stock rises 16%

Pacira BioSciences, Inc. Just Missed Earnings - But Analysts Have Updated Their Models

Pacira BioSciences, Inc. (NasdaqGS:PCRX) announces an Equity Buyback for $150 million worth of its shares.

Getting In Cheap On Pacira BioSciences, Inc. (NASDAQ:PCRX) Might Be Difficult

Pacira BioSciences, Inc. to Report Q1, 2024 Results on May 07, 2024

Pacira BioSciences, Inc., Annual General Meeting, Jun 11, 2024

Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy (RMAT) Designation for the Treatment of Osteoarthritis of the Knee

Independent Director recently sold US$3.7m worth of stock

Independent Director notifies of intention to sell stock

Consensus EPS estimates fall by 21%

Full year 2023 earnings: EPS exceeds analyst expectations

Pacira BioSciences, Inc. Announces Departure of Charles A. Reinhart, III, as Chief Financial Officer, Effective September 30, 2024

Pacira BioSciences, Inc. to Report Q4, 2023 Results on Feb 29, 2024

Pacira BioSciences, Inc. Announces Publication of Pivotal Study of Exparel as a Sciatic Nerve Block in the Popliteal Fossa for Patients After Bunionectomy

Does Pacira BioSciences (NASDAQ:PCRX) Have A Healthy Balance Sheet?

High number of new directors

Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Low P/S No Reason For Excitement

Pacira BioSciences, Inc. Appoints Frank D. Lee as Chief Executive Officer, Effective January 2, 2024

Insider notifies of intention to sell stock

Pacira BioSciences, Inc. Announces FDA Approval of Expanded EXPAREL Label to Include Two Additional Nerve Block Indications

Pacira BioSciences, Inc. Updates Sales Guidance for the Full Year 2023

We Think Pacira BioSciences (NASDAQ:PCRX) Can Stay On Top Of Its Debt

Third quarter 2023 earnings released: EPS: US$0.23 (vs US$0.015 loss in 3Q 2022)

Pacira BioSciences, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Pacira Biosciences Appoints Four New Independent Directors to Its Board of Directors

Pacira BioSciences, Inc. Announces Retirement of David Stack to Retire as Its CEO

Price target decreased by 9.5% to US$55.89

New minor risk - Shareholder dilution

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Is Pacira BioSciences (NASDAQ:PCRX) Using Too Much Debt?

Pacira BioSciences, Inc. to Report Q2, 2023 Results on Aug 02, 2023

Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Intrinsic Value Is Potentially 26% Below Its Share Price

Chief Financial Officer recently sold US$915k worth of stock

Chief Operating Officer notifies of intention to sell stock

Independent Director notifies of intention to sell stock

Pacira BioSciences, Inc. Provides Earnings Guidance for the Full-Year 2023

First quarter 2023 earnings: EPS misses analyst expectations

Is Pacira BioSciences (NASDAQ:PCRX) A Risky Investment?

Independent Director notifies of intention to sell stock

Full year 2022 earnings: EPS misses analyst expectations

We Think Pacira BioSciences (NASDAQ:PCRX) Can Stay On Top Of Its Debt

Insufficient new directors

Consensus forecasts updated

Third quarter 2022 earnings released: US$0.015 loss per share (vs US$0.40 profit in 3Q 2021)

Pacira BioSciences, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Assessing Pacira BioSciences' Growth Prospects

President of Rest of World notifies of intention to sell stock

Insufficient new directors

Pacira BioSciences guides Q3 revenue below consensus

Pacira, Sevāredent team up to expand access to pain drug Exparel for dental procedures

Pacira Biosciences Announces Positive Topline Data from Phase 3 Study of Exparel as A Single-Dose Sciatic Nerve Block in the Popliteal Fossa for Bunionectomy

Pacira BioSciences, Inc. Receives Positive CHMP Opinion for Exparel® for the Treatment of Postsurgical Pain in Children Aged 6 or Older

EMA panel backs expanding indication for Pacira's postsurgical pain treatment in kids